Showing 5201-5210 of 5644 results for "".
- Trial of Tele-Ophthalmology System at Regional Health Board in Scotland Shows Promising Resultshttps://modernod.com/news/trial-of-tele-ophthalmology-system-at-regional-health-board-in-scotland-shows-promising-results/2476808/Researchers at the University of Strathclyde and NHS Forth Valley in Scotland have developed a tele-ophthalmology system that, according to recent data, has reduced the need for follow-up appointments and waiting times for treatments in over 50% of cases, according to a
- Oculus Introduces Pentacam AXL Wavehttps://modernod.com/news/oculus-introduces-pentacam-axl-wave/2479548/Oculus has announced that it plans to introduce its next-generation Pentacam—the Pentacam AXL Wave. The new Pentacam AXL Wave is the first device to combine Scheimpflug tomography with axial length, total eye wavefront, objective refraction, and retroillumination, according to Oculus. New
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- OcuNexus Therapeutics Making Progress with Inflammasome Inhibition Program in Ophthalmic Diseasehttps://modernod.com/news/ocunexus-therapeutics-making-significant-progress-with-inflammasome-inhibition-program-in-ophthalmic-disease/2479550/OcuNexus Therapeutics announced that it has strengthened its board of directors with the addition of Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. OcuNexus Therapeutics is a clinical stage biotechnology company develop
- Bausch Health CEO: Big Pharma Will Survive US Drug Regulationshttps://modernod.com/news/bausch-health-ceo-big-pharma-will-survive-us-drug-regulations/2476798/Bausch Health Chariman and CEO Joseph C. Papa told CNBC on Wednesday that he isn’t too concerned about the future of the pharmaceutical industry despite pledges from Congress to lower
- Optronics Introduces Microcast Pro Medical Grade Microscope Video Camera Platformhttps://modernod.com/news/optronics-introduces-microcast-pro-medical-grade-microscope-video-camera-platform/2476796/Optronics announced the introduction of the next generation Microcast, the Microcast 4K PRO 3CMOS 2160p Ultra High Definition, and Microcast HD PRO 3CMOS 1080p high definition microscope video cameras for surgical and other technical microscope imaging applications including pathology, research,
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidatehttps://modernod.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/TopiVert Pharma announced topline results from THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1, a multicenter, randomized, double-masked, placebo-controlled phase 2b/3
- Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DMEhttps://modernod.com/news/alimera-announces-iluvien-regulatory-approval-in-australia-for-the-treatment-of-dme/2479552/Alimera Sciences announced that the Australian Therapeutic Goods Administration (TGA), the division of the Australian Department of Health that oversees the availability of medical products, has approved Iluvien (190 micrograms intravitreal implant in applicator) for the treatment of diabetic mac
- Staar Surgical Announces Submission of Presbyopia Clinical Trial Datahttps://modernod.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/Staar Surgical announced the submission of its multisite European pivotal clinical trial data for the EVO+ Visian ICL with Aspheric (EDOF) Optic, a lens that is designed to provide correction or reduction of myopia or hyperopia and presbyopia. Results from the clinical trial were submitted to DEK